Abstract
Chimeric antigen receptor (CAR) T cell immunotherapy in solid cancer is severely limited by the absence of ideal targets. In this issue of Cancer Cell, Bergaggio et al. find that anaplastic lymphoma kinase (ALK) inhibitors can enhance the function of ALK-specific CAR T cells against neuroblastoma by increasing target density in cancer cells.
Copyright © 2023 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, N.I.H., Extramural
MeSH terms
-
Humans
-
Immunotherapy
-
Immunotherapy, Adoptive
-
Neuroblastoma* / pathology
-
Protein Kinase Inhibitors
-
Receptor Protein-Tyrosine Kinases / genetics
-
Receptors, Antigen, T-Cell / genetics
-
Receptors, Chimeric Antigen* / genetics
-
T-Lymphocytes
Substances
-
Receptors, Chimeric Antigen
-
Protein Kinase Inhibitors
-
Receptor Protein-Tyrosine Kinases
-
Receptors, Antigen, T-Cell